Thyroid disorders are among the most common chronic conditions encountered in lactation care. Concerns about medication safety, milk supply, and infant outcomes can create anxiety for families and sometimes lead to premature weaning. Fortunately, guidance from leading organizations like the Breastfeeding Network, La Leche League International (LLLI), and the American Thyroid Association (ATA) consistently supports continued breastfeeding in most thyroid conditions when appropriately treated.
Rather than framing thyroid medication as a barrier to breastfeeding, practitioners should view it as a key support for lactation physiology and maternal health.
Why Thyroid Function Is Central to Lactation
Thyroid hormones are essential for:
- Mammary gland development
- Initiation of lactogenesis II
- Ongoing regulation of milk production
Research supports that untreated hypothyroidism or hyperthyroidism, rather than medication, poses the greater risk to breastfeeding success, particularly in the early postpartum period. Parents with poorly controlled thyroid disease may experience delayed milk onset, low supply, fatigue, or mood symptoms that interfere with feeding and bonding.
Hypothyroidism and Breastfeeding
Levothyroxine (T4): Standard of Care
Safety in breast milk
Levothyroxine is biologically identical to endogenous T4 and is a normal component of human milk. Studies show that replacement-dose therapy results in minimal transfer into milk and has not been associated with adverse effects in breastfed infants.
Levothyroxine is fully compatible with breastfeeding and does not require dose timing around feeds.
Impact on milk supply
Importantly, correcting hypothyroidism with levothyroxine can improve milk production. ATA patient materials note that achieving euthyroid status postpartum supports maternal recovery and normal lactation physiology.
Practice implications
- Dose adjustments are common postpartum and during lactation.
- Subtherapeutic dosing may present as persistent low milk supply.
- Supporting adherence and follow-up testing is a lactation-supportive intervention.
Liothyronine (T3) and Combination Therapy
Liothyronine (T3), alone or combined with T4, is less commonly prescribed but may be used in select cases.
What we know
- Small amounts of T3 may enter breast milk.
- At physiologic doses, infant exposure remains low.
- Because T3 is more biologically active, clinical judgment and coordination among providers are advised.
Lactation perspective
Most breastfeeding parents do well on standard T4 therapy alone. Combination therapy may warrant closer observation of infant growth and feeding, but is not an automatic contraindication to breastfeeding.
Hyperthyroidism and Breastfeeding
Methimazole / Carbimazole
Methimazole (or carbimazole) is widely used for hyperthyroidism and is generally considered acceptable during lactation, but compatibility is often dose dependent.
Breastfeeding safety
- Methimazole transfers into milk in measurable but generally low amounts; Hale’s data reports transfer ranging from 5% to 14%.
- Studies show normal infant thyroid function when maternal doses remain within recommended limits, though exposure may increase at higher doses.
Clinical guidance
- Breastfeeding can usually continue while on methimazole, particularly at lower or standard doses.
- If a parent is taking higher doses, some clinicians may recommend a half-breastmilk/half-formula feeding approach depending on the clinical situation.
- Occasional monitoring of the infant’s thyroid levels may be considered, especially with higher-dose therapy.
- Dividing doses or taking medication after feeds may slightly reduce exposure, though this is not strictly necessary.
Propylthiouracil (PTU)
In our data, propylthiouracil (PTU) is rated L2 and is identified as the best antithyroid medicine for breastfeeding. PTU enters breast milk in very small quantities, which supports its compatibility with lactation when clinically indicated.
Radioactive Iodine: A Clear Exception
Radioactive iodine (I 131) is rated L5 and is generally considered incompatible with breastfeeding. However, guidance in specialized references may distinguish between diagnostic and therapeutic use, and whether breastfeeding interruption is temporary or permanent can depend on the clinical dose and treatment context.
- I 131 concentrates in breast tissue and breast milk, creating significant potential infant exposure.
- Resuming breastfeeding may be possible in some clinical situations, but this would require more information about the dose, frequency, and reason for receiving I 131; higher therapeutic exposures are generally treated as incompatible with breastfeeding.
Some diagnostic nuclear medicine procedures using short acting isotopes may require only temporary interruption, but these decisions must be guided by specialized references.
Postpartum Thyroiditis: A Common, Overlooked Factor
Postpartum thyroiditis is a frequently underrecognized condition affecting lactation.
- It may present with transient hyperthyroidism, hypothyroidism, or both.
- Symptoms can mimic postpartum mood disorders or “low supply” scenarios.
- Management depends on phase and symptom severity; breastfeeding is typically supported throughout.
For lactation consultants, recognizing when symptoms fall outside normal postpartum adjustment is critical for timely referral.
Hale’s L1–L5 Breastfeeding Risk Category System and Thyroid Medications
Dr. Thomas Hale pioneered a widely recognized category system used to communicate lactation safety at a glance:
Category Meaning
L1 Safest
L2 Safer
L3 Moderately Safe
L4 Possibly Hazardous
L5 Contraindicated
Hale’s often provides safer options along with commentary about clinical judgment for drugs rated L4 or L5,
This is where Hale’s moves from informative to actionable. For time-strapped providers juggling risk and benefit, this shortcut to safer recommendations is invaluable. HalesMeds (lactation database) rates the following thyroid medications as follows:
- [L1] Levothyroxine (T4)
- [L2] Liothyronine (T3)
- [L2] Methimazole / Carbimazole
- [L2] Propylthiouracil (PTU)
- [L5] Radioactive Iodine (I 131)
Infant Monitoring: Reassurance With Vigilance
Across all sources, consensus is clear:
- Routine infant thyroid testing is not required solely due to parental thyroid medication.
- Monitor infants for normal growth, feeding effectiveness, and development.
- Laboratory monitoring may be considered with higher-dose antithyroid therapy or concerning symptoms.
This balanced approach helps prevent unnecessary anxiety and weaning.
Key Counseling Points for Lactation Consultants
- Thyroid medications are usually compatible with breastfeeding.
- Untreated thyroid disease poses greater risk to milk supply than medication does.
- Encourage routine postpartum thyroid testing and follow-up.
- Collaborate with endocrinology and pediatrics when concerns arise.
- Reinforce that continued breastfeeding is often the healthiest option for both parent and infant.
What About Armour Thyroid or NP Thyroid?
Armour Thyroid and NP Thyroid are desiccated thyroid products containing both T4 and T3. Although they are not discussed as often as levothyroxine, available lactation information suggests that needing thyroid replacement is not, by itself, a reason to stop breastfeeding. Because these products include T3 as well as T4, clinicians may prefer individualized follow-up and may still consider levothyroxine the standard first-line option when appropriate.
Bottom Line
Expert evidence from various sources consistently supports breastfeeding during appropriately managed thyroid disease. Lactation consultants play a vital role in reframing thyroid medication as a supportive therapy for lactation, reducing misinformation, and helping families meet both endocrine and breastfeeding goals.
________________________________________
References
1. The Breastfeeding Network (UK). Thyroid Disease and Breastfeeding. https://www.breastfeedingnetwork.org.uk/factsheet/thyroid/
2. La Leche League International. Breastfeeding and Thyroidism. https://llli.org/breastfeeding-info/breastfeeding-and-thyroidism/
3. American Thyroid Association. Clinical Thyroidology for Patients: Antithyroid Drugs & Radioactive Iodine (May 2017). https://www.thyroid.org/patient-thyroid-information/ct-for-patients/may-2017/vol-10-issue-5-p-3-7/
4. HalesMeds. https://www.halesmeds.com/login
